Browse By: Country ι Category ι Tag
Home  »  DelveInsight

DelveInsight Market Research Reports

DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

We combine industry expertise with innovation by collecting, analyzing and communicating to deliver critical information to leading decision makers in the Approved drugs market, Active Pharmaceutical (API) market, Generic market and Drug’s Research and development. We help Drug developing companies, Generics and API manufacturing companies to strategize and identify the right thrust areas and potential customers for their existing and new products.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one - collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.


PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products. Scope • The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors • The report provides the marketed drugs information
Published Date: Feb 2017
Published By: DelveInsight

Price: $2950
Natural Killer Cells - Competitive Landscape, Pipeline and Market Analysis, 2017
This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products. Scope • The report provides competitive pipeline landscape of Natural Killer Ce
Published Date: Feb 2017
Published By: DelveInsight

Price: $2450
Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
Scope • The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors • The report provides the marketed drugs information including its sales, development activities and details of patent expiry • The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information • Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type • The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profilin
Published Date: Feb 2017
Published By: DelveInsight

Price: $2450
Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017
Scope • The report provides competitive pipeline landscape of Immune Checkpoints Activators • The report provides the marketed drugs information including its sales, development activities and details of patent expiry • The report provides the insight of current and future market for Immune Checkpoints Activators • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information • Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type • The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profilin
Published Date: Feb 2017
Published By: DelveInsight

Price: $2250
Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017
Scope • The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy • The report provides the marketed drugs information including its sales, development activities and details of patent expiry • The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information • Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type • The report reviews key players involved in the therapeutics developmen
Published Date: Feb 2017
Published By: DelveInsight

Price: $2750
LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017
DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2017 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Published Date: Feb 2017
Published By: DelveInsight

Price: $1250
Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017
This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years. Recent report of DelveInsight covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer.
Published Date: Feb 2017
Published By: DelveInsight

Price: $2450
Ovarian Cancer - Treatment Landscape & Competitive Analysis, 2017
Note: This report will be delivered to the client in 1-2 business days Report Highlights: • The new report, provides a Ovarian Cancer Treatment Landscape across the globe • The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc. • Comparative analysis of marketed drugs by therapy, cost of treatment and Therapeutic Class. • Coverage of the Ovarian Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival • The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide market barriers, market drivers and opportunities • Provides Phase
Published Date: Feb 2017
Published By: DelveInsight

Price: $2450
Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017
Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epidemiology of the disease. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline. It analyses Insulin Biosimilar industry and discusses the key market trends, major players, market assessment of 6 marketed insulin and the types of insulin with the length activity available in market. Report provides an update on the recent collaborations occurring in the insulin biosimilar market and the companies looking for partnership for the same. Scope: - Coverage of global insulin biosimilar under development across the globe - Sales forecast for marketed insulin from 2015 to 2017 - Detailed information on product description and rel
Published Date: Feb 2017
Published By: DelveInsight

Price: $1450
Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs, its patent and exclusivity details. - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023. - It also provides Market size of Alpha-Antitrypsin Deficiency for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Published Date: Feb 2017
Published By: DelveInsight

Price: $4950
Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023
DelveInsight’s “Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023. According to DelveInsight, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023. As per DelveInsight’s estimation, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023. The report is built using data a
Published Date: Feb 2017
Published By: DelveInsight

Price: $4950
Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- United States
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.92% from 2013-2023 and reach up to 27,114 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors a
Published Date: Jan 2017
Published By: DelveInsight

Price: $2450
Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- EU5
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.71% from 2013-2023 and reach up to 30,328 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors a
Published Date: Jan 2017
Published By: DelveInsight

Price: $2450
Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast-2023- Japan
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.73% from 2013-2023 and reach up to 7,025 cases in the year 2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors an
Published Date: Jan 2017
Published By: DelveInsight

Price: $1750
Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast-2023
As per DelveInsight’s estimation, the global market size of Cytomegalovirus (CMV) infection shall reach to USD 1,210.4 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR 6.57% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.44% from the 2013-2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs. - The Report also covers the detailed global historical and forecasted epidemiol
Published Date: Jan 2017
Published By: DelveInsight

Price: $4950
Graft Versus Host Disease (GVHD) - Epidemiology Insights-2023
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). DelveInsight forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight’s estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.80% from 2013-2023. The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per DelveInsight forecasts, the global diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall incr
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023
The report considers the transplant patients, HIV patients and Infants under high risk for CMV infections and epidemiology forecast for these high risk categories have also been taken into consideration. Of The 7 Major Markets, U.S. has the highest number of CMV Prevalent cases and Spain has the least number of CMV Prevalent cases. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% to 172,864 cases in 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope • Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis and disease
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Opana ER-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Opana ER based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Opana ER on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Opana ER with location details • Patent Expiry Timeline and Excl
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Migraine-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Migraine Report is to understand the market and pipeline status of the drugs around the Migraine to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Migraine. While the leading brands, companies and chemica
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Ovarian Cancer Report is to understand the market and pipeline status of the drugs around the Metastatic Ovarian Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metast
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Renal Stones/Calculi-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Guillain- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Guillain subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Guillain market. • Identifying prevalent patient populations as well as risk factors in the global Guillain ma
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Allergic Rhino-Conjunctivitis-Pipeline Insights, 2017
DelveInsight’s, “ Allergic Rhino-Conjunctivitis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Allergic Rhino-Conjunctivitis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Allergic Rhino-Conjunctivitis. DelveInsight’s Report also ass
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hemorrhagic Shock-Pipeline Insights, 2017
DelveInsight’s, “ Hemorrhagic Shock-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hemorrhagic Shock. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hemorrhagic Shock. DelveInsight’s Report also assesses the Hemorrhagic Shock therape
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Insights, 2017
DelveInsight’s, “ Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Primary Progressive Multiple Sclerosis (PPMS). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Primary Progressive Multiple Sc
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD28 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD28 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD28 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD28 Antibody. DelveInsight’s Report also assesses the Anti-CD28 Antibody therap
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Histone Deacetylase 1 (HDAC1) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Histone Deacetylase 1 (HDAC1) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Histone Deacetylase 1 (HDAC1) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Histone Deacetylase 1 (HDAC1) Inhibitors. D
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selectin Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Selectin Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selectin Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selectin Inhibitors. DelveInsight’s Report also assesses the Selectin Inhibitors th
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Optinate-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Optinate based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Optinate on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Optinate with location details • Patent Expiry Timeline and Excl
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Moderate Pain Report is to understand the market and pipeline status of the drugs around the Moderate Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Moderate Pain. While the leading brands, c
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Metastatic Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Metastatic Pancreatic Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Pancreatic Cancer Report is to understand the market and pipeline status of the drugs around the Metastatic Pancreatic Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across t
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Respiratory Tract Infections-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Huntingtons Disease- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Huntington's Disease subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Huntington's Disease market. • Identifying prevalent patient populations as well as risk factors i
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Alopecia-Pipeline Insights, 2017
DelveInsight’s, “ Alopecia-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Alopecia. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Alopecia. DelveInsight’s Report also assesses the Alopecia therapeutics by Monotherapy, Combination pr
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hemostasis-Pipeline Insights, 2017
DelveInsight’s, “ Hemostasis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hemostasis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hemostasis. DelveInsight’s Report also assesses the Hemostasis therapeutics by Monotherapy, Combin
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Proctitis-Pipeline Insights, 2017
DelveInsight’s, “ Proctitis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Proctitis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Proctitis. DelveInsight’s Report also assesses the Proctitis therapeutics by Monotherapy, Combinatio
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD3 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD3 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD3 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD3 Antibody. DelveInsight’s Report also assesses the Anti-CD3 Antibody therapeuti
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Histone Deacetylase 1 (HDAC8) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Histone Deacetylase 1 (HDAC8) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Histone Deacetylase 1 (HDAC8) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Histone Deacetylase 1 (HDAC8) Inhibitors. D
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selective COX Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Selective COX Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selective COX Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selective COX Inhibitors. DelveInsight’s Report also assesses the Selecti
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Optisulin-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Optisulin based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Optisulin on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Optisulin with location details • Patent Expiry Timeline and E
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Multiple Myeloma (Kahlers Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Multiple Myeloma (Kahler's Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Multiple Myeloma (Kahler's Disease) Report is to understand the market and pipeline status of the drugs around the Multiple Myeloma (Kahler's Disease) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of a
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Renal Cell Carcinoma Report is to understand the market and pipeline status of the drugs around the Metastatic Renal Cell Carcinoma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Rheumatoid Arthritis-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Myasthenia Gravis- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Myasthenia Gravis subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Myasthenia Gravis market. • Identifying prevalent patient populations as well as risk factors in the
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Alpha- Antitrypsin Deficiency-Pipeline Insights, 2017
DelveInsight’s, “ Alpha- Antitrypsin Deficiency-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Alpha- Antitrypsin Deficiency. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Alpha- Antitrypsin Deficiency. DelveInsight’s Report also ass
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hepatic- Colorectal Metastasis-Pipeline Insights, 2017
DelveInsight’s, “ Hepatic - Colorectal Metastasis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hepatic - Colorectal Metastasis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hepatic - Colorectal Metastasis. DelveInsight’s Report al
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Progressive Multifocal Leukoencephalopathy-Pipeline Insights, 2017
DelveInsight’s, “ Progressive Multifocal Leukoencephalopathy-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Progressive Multifocal Leukoencephalopathy. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Progressive Multifocal Leukoencephalo
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD30 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD30 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD30 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD30 Antibody. DelveInsight’s Report also assesses the Anti-CD30 Antibody therap
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Histone Deacetylase 2 (HDAC2) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Histone Deacetylase 2 (HDAC2) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Histone Deacetylase 2 (HDAC2) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Histone Deacetylase 2 (HDAC2) Inhibitors. D
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selective COX-2 Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Selective COX-2 Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selective COX-2 Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selective COX-2 Inhibitors. DelveInsight’s Report also assesses the S
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Optruma-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Optruma based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Optruma on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Optruma with location details • Patent Expiry Timeline and Exclusi
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Multiple Sclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Multiple Sclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Multiple Sclerosis Report is to understand the market and pipeline status of the drugs around the Multiple Sclerosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Multiple Sclerosis. While t
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Mixed Dyslipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Mixed Dyslipidemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Mixed Dyslipidemia Report is to understand the market and pipeline status of the drugs around the Mixed Dyslipidemia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Mixed Dyslipidemia. While t
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Schizophrenia-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Narcolepsy- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Narcolepsy subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Narcolepsy market. • Identifying prevalent patient populations as well as risk factors in the global Narcole
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Amenorrhea-Pipeline Insights, 2017
DelveInsight’s, “ Amenorrhea-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Amenorrhea. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Amenorrhea. DelveInsight’s Report also assesses the Amenorrhea therapeutics by Monotherapy, Combin
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hepatic (Liver) Tumor-Pipeline Insights, 2017
DelveInsight’s, “ Hepatic (Liver) Tumor-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hepatic (Liver) Tumor. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hepatic (Liver) Tumor. DelveInsight’s Report also assesses the Hepatic (Live
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Progressive Supranuclear Palsy-Pipeline Insights, 2017
DelveInsight’s, “ Progressive Supranuclear Palsy -Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Progressive Supranuclear Palsy . The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Progressive Supranuclear Palsy . DelveInsight’s Report al
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD33 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD33 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD33 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD33 Antibody. DelveInsight’s Report also assesses the Anti-CD33 Antibody therap
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Histone Deacetylase 3 (HDAC3) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Histone Deacetylase 3 (HDAC3) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Histone Deacetylase 3 (HDAC3) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Histone Deacetylase 3 (HDAC3) Inhibitors. D
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selective Dipeptidyl Peptidase-4 (DPP-4) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Selective Dipeptidyl Peptidase-4 (DPP-4) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selective Dipeptidyl Peptidase-4 (DPP-4) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selective Dipeptidyl
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Orencia-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Orencia based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Orencia on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Orencia with location details • Patent Expiry Timeline and Exclusi
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Musculoskeletal Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Musculoskeletal Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Musculoskeletal Pain Report is to understand the market and pipeline status of the drugs around the Musculoskeletal Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Musculoskeletal Pain.
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Myasthenia Gravis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Myasthenia Gravis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Myasthenia Gravis Report is to understand the market and pipeline status of the drugs around the Myasthenia Gravis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Myasthenia Gravis. While the l
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Seborrhea-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Lennox Gastaut Syndrome- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Lennox Gastaut Syndrome subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Lennox Gastaut Syndrome market. • Identifying prevalent patient populations as well as risk fac
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Amyloidosis-Pipeline Insights, 2017
DelveInsight’s, “ Amyloidosis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Amyloidosis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Amyloidosis. DelveInsight’s Report also assesses the Amyloidosis therapeutics by Monotherapy, Co
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hepatic Edema-Pipeline Insights, 2017
DelveInsight’s, “ Hepatic Edema-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hepatic Edema. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hepatic Edema. DelveInsight’s Report also assesses the Hepatic Edema therapeutics by Monothe
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Proliferative Vitreoretinopathy (PVR)-Pipeline Insights, 2017
DelveInsight’s, “ Proliferative Vitreoretinopathy (PVR)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Proliferative Vitreoretinopathy (PVR). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Proliferative Vitreoretinopathy (PVR). DelveIns
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD37 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD37 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD37 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD37 Antibody. DelveInsight’s Report also assesses the Anti-CD37 Antibody therap
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Histone Deacetylase 6 (HDAC6) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Histone Deacetylase 6 (HDAC6) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Histone Deacetylase 6 (HDAC6) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Histone Deacetylase 6 (HDAC6) Inhibitors. D
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selective Glucocorticoid Receptor Agonists-Pipeline Insights, 2017
DelveInsight’s, “Selective Glucocorticoid Receptor Agonists-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selective Glucocorticoid Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selective Glucocorticoid Receptor Agoni
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Pentasa Enema-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Pentasa Enema based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Pentasa Enema on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Pentasa Enema with location details • Patent Expiry Ti
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Mycoses-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Mycoses-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Mycoses Report is to understand the market and pipeline status of the drugs around the Mycoses to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Mycoses. While the leading brands, companies and chemicals a
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Myelodysplastic Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Myelodysplastic Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Myelodysplastic Syndrome Report is to understand the market and pipeline status of the drugs around the Myelodysplastic Syndrome to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Myelodysp
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Sedation-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
AIDS Related Kaposis Sarcoma- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key AIDS Related Kaposi's Sarcoma subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global AIDS Related Kaposi's Sarcoma market. • Identifying prevalent patient populations as well
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Anal Fissure-Pipeline Insights, 2017
DelveInsight’s, “ Anal Fissure-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anal Fissure. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anal Fissure. DelveInsight’s Report also assesses the Anal Fissure therapeutics by Monotherapy
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hepatic Encephalopathy-Pipeline Insights, 2017
DelveInsight’s, “ Hepatic Encephalopathy-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hepatic Encephalopathy. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hepatic Encephalopathy. DelveInsight’s Report also assesses the Hepatic En
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Proteinuria-Pipeline Insights, 2017
DelveInsight’s, “ Proteinuria-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Proteinuria. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Proteinuria. DelveInsight’s Report also assesses the Proteinuria therapeutics by Monotherapy, Co
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD38 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD38 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD38 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD38 Antibody. DelveInsight’s Report also assesses the Anti-CD38 Antibody therap
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
HIV Attachment Inhibitor-Pipeline Insights, 2017
DelveInsight’s, “HIV Attachment Inhibitor-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the HIV Attachment Inhibitor. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for HIV Attachment Inhibitor. DelveInsight’s Report also assesses the HIV Att
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Selective Serotonin Reuptake Inhibitors (SSRI)-Pipeline Insights, 2017
DelveInsight’s, “Selective Serotonin Reuptake Inhibitors (SSRI)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Selective Serotonin Reuptake Inhibitors (SSRI). The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Selective Serotonin Reuptake In
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Pentaxim-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Pentaxim based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Pentaxim on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Pentaxim with location details • Patent Expiry Timeline and Excl
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Mycosis Fungoides-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Mycosis Fungoides-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Mycosis Fungoides Report is to understand the market and pipeline status of the drugs around the Mycosis Fungoides to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Mycosis Fungoides. While the l
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Myelofibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Myelofibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Myelofibrosis Report is to understand the market and pipeline status of the drugs around the Myelofibrosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Myelofibrosis. While the leading brands, c
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Seizures-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Osteosarcoma- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Osteosarcoma subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Osteosarcoma market. • Identifying prevalent patient populations as well as risk factors in the global Ost
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Anal Fistula-Pipeline Insights, 2017
DelveInsight’s, “ Anal Fistula -Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anal Fistula . The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anal Fistula . DelveInsight’s Report also assesses the Anal Fistula therapeutics by Monothe
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Hepatitis A-Pipeline Insights, 2017
DelveInsight’s, “ Hepatitis A-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Hepatitis A. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Hepatitis A. DelveInsight’s Report also assesses the Hepatitis A therapeutics by Monotherapy, Co
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Pruritus-Pipeline Insights, 2017
DelveInsight’s, “ Pruritus-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Pruritus. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Pruritus. DelveInsight’s Report also assesses the Pruritus therapeutics by Monotherapy, Combination pr
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Anti-CD4 Antibody-Pipeline Insights, 2017
DelveInsight’s, “Anti-CD4 Antibody-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anti-CD4 Antibody. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anti-CD4 Antibody. DelveInsight’s Report also assesses the Anti-CD4 Antibody therapeuti
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
HIV Protease Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “HIV Protease Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the HIV Protease Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for HIV Protease Inhibitors. DelveInsight’s Report also assesses the HIV Protea
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitors-Pipeline Insights, 2017
DelveInsight’s, “Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Semicarbazide
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Plavix-Drug Insights, 2017
Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. Scope • A review of the Plavix based on information derived from company and industry-specific sources • Coverage of the Marketed data of the Plavix on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Plavix with location details • Patent Expiry Timeline and Exclusivit
Published Date: Jan 2017
Published By: DelveInsight

Price: $1000
Myocardial Infarction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Myocardial Infarction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Myocardial Infarction Report is to understand the market and pipeline status of the drugs around the Myocardial Infarction to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Myocardial Infarct
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Myoclonic Seizures-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Myoclonic Seizures-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Myoclonic Seizures Report is to understand the market and pipeline status of the drugs around the Myoclonic Seizures to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Myoclonic Seizures. While t
Published Date: Jan 2017
Published By: DelveInsight

Price: $2000
Septicaemia-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250
Mucopolysaccharidosis- Epidemiology Forecast To 2023
Please note: This report requires 5-7 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication. Scope of the Report • The Report includes the prevalent population and how will it change over the next eight years. • Prevalent or incident cases segmented by age and sex. • Coverage of key Mucopolysaccharidosis subpopulations and its prevalent or incident cases • The key differences in epidemiology patterns across the seven market segments Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Mucopolysaccharidosis market. • Identifying prevalent patient populations as well as risk factors
Published Date: Jan 2017
Published By: DelveInsight

Price: $2750
Anaplastic Astrocytoma-Pipeline Insights, 2017
DelveInsight’s, “ Anaplastic Astrocytoma-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Astrocytoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anaplastic Astrocytoma. DelveInsight’s Report also assesses the Anaplastic
Published Date: Jan 2017
Published By: DelveInsight

Price: $1250

Back To Top